|
JP2020105162A
|
|
Combination therapy including kras g12c inhibitor and one or more additional pharmaceutically active agents for treatment of cancers
|
|
JP2020090482A
|
|
Improved synthesis of key intermediate of kras g12c inhibitor compound
|
|
JP2018199667A
|
|
Compounds that inhibit mcl-1 protein
|
|
JP2018154616A
|
|
Low-viscosity, high-concentration evolocumab formulations and methods of making the same
|
|
JP2018076351A
|
|
Methods for treating homozygous familial hypercholesterolemia
|
|
JP2018123119A
|
|
Gastro-retentive modified release dosage forms for oprozomib and process to make the same
|
|
JPH08173185A
|
|
Production of stimulating factor for human granulocytic macrophage colony
|
|
JPH0833487A
|
|
Dna transformation vector for indigo formation by micro-organism
|
|
US5278062A
|
|
Proteolytic enzymes
|
|
US5273882A
|
|
Method and kit for performing nucleic acid hybridization assays
|
|
IL99611D0
|
|
Dna plasmids
|
|
US4977092A
|
|
Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
|
|
JPS63269983A
|
|
Production of human granulocyte macrophase colony stimulating factor
|
|
KR950000883B1
|
|
Fermentation method for hepatitis vaccine production
|
|
ES2005541A6
|
|
Hybrid promoter controlling exogenous gene transcription
|
|
ES2003521A6
|
|
Lysis buffer for yeast cells
|
|
GR862720B
|
|
Fermentation methods for hepatitis vaccine production
|
|
ZA8608612B
|
|
Lysis method and buffer for extraction of hepatitis b surface antigen from yeast cells
|
|
GR862721B
|
|
Lysis method and buffer for extraction of hepatitis b surface antigen from yeast cells
|
|
ZA8608611B
|
|
Fermentation methods for hepatitis vaccine production
|
